Phase 2b Elumina trial; topline data anticipated in Q4 2026 (ClinicalTrials.gov: NCT06524830) AtaiBeckley plans to advance VLS-01 into major depressive disorder (MDD) in Phase 3, with generalized ...

While a single fecal microbiota transplantation session did not significantly improve multidrug-resistant organism ...

Our brains are large compared with other animals, so it is tempting to assume there was an evolutionary advantage to them – ...

Recent research published in the Journal of Psychopharmacology suggests that cannabidiol, a non-intoxicating compound found ...

Most people can feel the gap without thinking about it. One hand writes neatly, throws cleanly, and handles tools with ease.

Summary: A new study demonstrates that the BCG vaccine actively remodels the immune environment surrounding the human brain and spinal cord. By tracking older adults over 12 months, the research team ...

A systematic review and meta-analysis of 28 cohort-based studies found a weak but statistically significant association ...

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage company focused on developing promising new therapies in oncology and obesity, today announced the ...

In patients with septic shock, early vasopressor therapy plus restricted fluid administration does not improve 90-day outcomes compared with greater fluid administration with later vasopressor use.

AVE has made a breakthrough with a phase III insomnia trial for its soft gel cannabidiol to manage sleeplessness. ... Read ...

The trial is real, and it is a meaningful step. It is also, by design, small, tightly controlled, and years away from ...

Solving complex optimization problems is central to many modern technologies, from logistics and financial modeling to chip ...